查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951910

基因突變分析市場分析及預測（至2035年）：按類型、產品類型、服務、技術、應用、最終用戶、組件、部署類型和功能分類

Genetic Mutation Analysis Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 331 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

基因突變分析市場預計將從2024年的65億美元成長到2034年的185億美元，複合年成長率約為11.6%。基因突變分析市場涵蓋用於識別和解讀基因突變的技術和服務，這些技術和服務對於個人化醫療、診斷和治療研發至關重要。這些技術和服務包括次世代定序、PCR和生物資訊學工具。遺傳疾病的增加和基因組學技術的進步正在推動市場需求，並促進精準醫療和標靶治療的創新。

基因突變分析市場正經歷強勁成長，這主要得益於精準醫療和個人化醫療保健的進步。定序技術領域處於領先地位，其中次世代定序(NGS) 技術憑藉其準確性和成本效益，推動了顯著的改進。該領域以全基因測序為主導，它能夠提供關於基因突變的全面資訊；其次是靶向定序，它能夠對特定目標基因進行重點分析。軟體和服務領域也呈現出良好的成長勢頭，主導生物資訊解決方案尤為突出。這些解決方案對於解讀和管理日益成長的基因數據至關重要。雖然基於雲端的生物資訊平台因其擴充性和易用性而日益普及，但對於那些優先考慮資料安全和管理的機構而言，本地部署解決方案仍然十分重要。腫瘤學和罕見疾病領域的新興應用進一步推動了市場擴張，凸顯了基因突變分析在醫學研究和推進治療策略方面的重要性。

市場區隔
類型 單核苷酸多態性（SNP）分析、拷貝數變異（CNV）分析、大規模突變分析
產品 試劑/試劑盒、設備、軟體、耗材
服務 基因檢測服務、數據解讀服務、諮詢服務
科技 次世代定序(NGS)、聚合酵素鏈鎖反應(PCR)、微陣列、桑格定序、CRISPR
應用領域 腫瘤學、心血管疾病、神經系統疾病、感染疾病、遺傳性疾病、藥物遺傳學
最終用戶 醫院和診所、研究機構、製藥和生物技術公司、診斷檢查室
成分 硬體、軟體和服務
實施表格 基於雲端的，本地部署的
功能 數據分析、數據管理、數據視覺化

基因突變分析市場呈現市場佔有率動態分佈的特點，主要參與者不斷透過新產品推出進行創新。定價策略競爭激烈，受到技術進步和精準醫療需求的影響。該領域正經歷新型診斷工具的快速成長，這些工具提高了突變檢測的準確性，促進了其在醫療保健系統中的應用。各公司正致力於建立策略聯盟，以擴展其產品系列併應對更廣泛的遺傳疾病。隨著遺傳疾病的增加，對先進突變分析解決方案的需求日益成長，市場正以驚人的速度發展。競爭基準分析表明，少數主要企業正在引領市場，並透過持續創新和策略聯盟來制定行業標準。監管的影響也十分顯著，嚴格的指導方針規範著產品開發和市場准入。北美在監管合規方面處於領先領先，而亞太地區由於政府的積極舉措，已成為主要市場參與者。競爭環境十分激烈，各公司都在加大研發投入以維持其技術優勢。法規環境既帶來挑戰也帶來機遇，在促進創新的同時，也確保了病人安全和基因檢測的有效性。

主要趨勢和促進因素：

在基因組技術和個人化醫療的推動下，基因突變分析市場持續穩定成長。一個顯著的趨勢是，市場對精準診斷的需求日益成長，精準診斷能夠根據每個人的基因譜制定更精準的治療方案。這項轉變源自於遺傳性疾病和癌症發生率的不斷上升，凸顯了早期準確檢測方法的重要性。此外，人工智慧 (AI) 和機器學習在基因分析中的應用，提升了資料解讀和預測能力。這些技術簡化了工作流程，並提高了突變檢測的準確性。另一個關鍵促進因素是公共和私營部門不斷增加的研發投入，旨在發現新的基因見解和治療標靶。消費者基因檢測服務的擴展也是一個顯著的趨勢，它使人們能夠更便捷地獲取基因訊息，並為個人提供個人化的健康資訊。新興市場擁有不斷完善的醫療基礎設施和日益普及的基因檢測，蘊藏著許多機會。隨著全球對遺傳健康風險的認知不斷提高，提供創新且經濟高效解決方案的公司有望佔據可觀的市場佔有率。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單核苷酸多態性（SNP）分析
    • 拷貝數變異（CNV）分析
    • 大規模突變分析
  • 市場規模及預測：依產品分類
    • 試劑和試劑盒
    • 分析器
    • 軟體
    • 消耗品
  • 市場規模及預測：依服務分類
    • 基因檢測服務
    • 數據解讀服務
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • 次世代定序（NGS）
    • 聚合酵素鏈鎖反應（PCR）
    • 微陣列
    • 桑格定序
    • CRISPR
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 神經系統疾病
    • 感染疾病
    • 遺傳性疾病
    • 藥物基因體學
  • 市場規模及預測：依最終用戶分類
    • 醫院和診所
    • 研究所
    • 製藥和生物技術公司
    • 診斷檢查室
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
  • 市場規模及預測：依發展狀況
    • 基於雲端的
    • 本地部署
  • 市場規模及預測：依功能分類
    • 數據分析
    • 資料管理
    • 數據視覺化

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Illumina
  • Thermo Fisher Scientific
  • Qiagen
  • Bio-Rad Laboratories
  • Agilent Technologies
  • Roche Diagnostics
  • Perkin Elmer
  • Pacific Biosciences
  • Oxford Nanopore Technologies
  • BGI Genomics
  • Genewiz
  • Genscript Biotech
  • LGC Biosearch Technologies
  • Takara Bio
  • Fluidigm Corporation
  • 10x Genomics
  • Personalis
  • Myriad Genetics
  • Genomic Health
  • Natera

第9章：關於我們

簡介目錄
Product Code: GIS10968

Genetic Mutation Analysis Market is anticipated to expand from $6.5 billion in 2024 to $18.5 billion by 2034, growing at a CAGR of approximately 11.6%. The Genetic Mutation Analysis Market encompasses technologies and services that identify and interpret genetic mutations, crucial for personalized medicine, diagnostics, and therapeutic development. This market includes next-generation sequencing, PCR, and bioinformatics tools. The rising incidence of genetic disorders and advancements in genomics propel demand, fostering innovation in precision medicine and targeted therapies.

The Genetic Mutation Analysis Market is experiencing robust growth, propelled by advancements in precision medicine and personalized healthcare. The sequencing technology segment is at the forefront, with next-generation sequencing (NGS) technologies driving significant performance due to their accuracy and cost-effectiveness. Within this segment, whole-genome sequencing outpaces others, offering comprehensive insights into genetic variations. Targeted sequencing follows closely, providing focused analysis on specific genes of interest. The software and services segment also shows promising growth, with bioinformatics solutions leading the way. These solutions are essential for data interpretation and management, supporting the increasing volume of genetic data. Cloud-based bioinformatics platforms are gaining popularity due to their scalability and accessibility, while on-premise solutions remain vital for institutions prioritizing data security and control. Emerging applications in oncology and rare diseases further fuel market expansion, highlighting the importance of genetic mutation analysis in advancing medical research and treatment strategies.

Market Segmentation
TypeSingle Nucleotide Polymorphism (SNP) Analysis, Copy Number Variation (CNV) Analysis, Large-Scale Mutation Analysis
ProductReagents and Kits, Instruments, Software, Consumables
ServicesGenetic Testing Services, Data Interpretation Services, Consultation Services
TechnologyNext-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, Sanger Sequencing, CRISPR
ApplicationOncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Genetic Disorders, Pharmacogenomics
End UserHospitals and Clinics, Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories
ComponentHardware, Software, Services
DeploymentCloud-Based, On-Premise
FunctionalityData Analysis, Data Management, Data Visualization

The Genetic Mutation Analysis Market is characterized by a dynamic distribution of market share, with key players consistently innovating through new product launches. Pricing strategies remain competitive, influenced by technological advancements and the demand for precision medicine. The sector is witnessing a surge in novel diagnostic tools that enhance mutation detection accuracy, driving adoption across healthcare systems. Companies are focusing on strategic collaborations to expand their product portfolios, thereby catering to a broader spectrum of genetic disorders. The market's evolution is propelled by the increasing prevalence of genetic diseases, necessitating advanced mutation analysis solutions. In terms of competition benchmarking, the market is dominated by a few major players who set industry standards through continuous innovation and strategic partnerships. Regulatory influences are significant, with stringent guidelines shaping product development and market entry. North America leads in regulatory compliance, while Asia-Pacific is emerging as a key player due to favorable government initiatives. The landscape is competitive, with companies investing in R&D to maintain a technological edge. The regulatory environment is both a challenge and an opportunity, fostering innovation while ensuring patient safety and efficacy in genetic testing.

Geographical Overview:

The genetic mutation analysis market is witnessing robust growth across various regions, each exhibiting unique dynamics. North America leads the market, propelled by advanced healthcare infrastructure and substantial investments in genomic research. The region's strong focus on precision medicine and personalized healthcare further fuels market expansion. Europe follows, with significant investments in genomic technologies and a well-established regulatory framework supporting market growth. The region's emphasis on healthcare innovation and research excellence enhances its competitive edge. In Asia Pacific, the market is expanding rapidly, driven by increasing healthcare expenditures and technological advancements in genomics. Emerging economies such as China and India are at the forefront, investing heavily in genomic research and infrastructure. Latin America and the Middle East & Africa are emerging growth pockets. Latin America is experiencing a surge in healthcare investments, while the Middle East & Africa are recognizing the potential of genetic mutation analysis in advancing healthcare outcomes and innovation.

Global tariffs and geopolitical tensions are significantly influencing the Genetic Mutation Analysis Market, particularly in East Asia. Japan and South Korea are experiencing increased costs due to tariffs on imported genetic sequencing equipment, prompting a shift towards enhancing domestic R&D capabilities. China is accelerating its efforts to develop indigenous biotechnologies in response to export restrictions, while Taiwan remains a pivotal player in biotech manufacturing but faces geopolitical vulnerabilities. The global market for genetic analysis is expanding robustly, driven by advancements in personalized medicine and genomics. By 2035, the market is expected to flourish with a focus on regional collaborations and technological innovation. Middle East conflicts, while primarily affecting energy prices, indirectly impact the cost structure of biotech supply chains, necessitating strategic resilience planning.

Key Trends and Drivers:

The Genetic Mutation Analysis Market is experiencing robust expansion, fueled by advancements in genomic technologies and personalized medicine. A significant trend is the growing demand for precision diagnostics, enabling more accurate treatment plans tailored to individual genetic profiles. This shift is driven by the increasing prevalence of genetic disorders and cancer, underscoring the necessity for early and precise detection methods. Moreover, the integration of artificial intelligence and machine learning in genetic analysis is enhancing data interpretation and predictive capabilities. These technologies are streamlining workflows and improving the accuracy of mutation detection. Another pivotal driver is the rising investment in research and development by both public and private sectors, aiming to uncover novel genetic insights and therapeutic targets. The expansion of direct-to-consumer genetic testing services is also a notable trend, democratizing access to genetic information and empowering individuals with personalized health insights. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and genetic testing adoption is on the rise. Companies that offer innovative, cost-effective solutions are poised to capture significant market share, particularly as awareness of genetic health implications grows globally.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Single Nucleotide Polymorphism (SNP) Analysis
    • 4.1.2 Copy Number Variation (CNV) Analysis
    • 4.1.3 Large-Scale Mutation Analysis
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Reagents and Kits
    • 4.2.2 Instruments
    • 4.2.3 Software
    • 4.2.4 Consumables
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Testing Services
    • 4.3.2 Data Interpretation Services
    • 4.3.3 Consultation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing (NGS)
    • 4.4.2 Polymerase Chain Reaction (PCR)
    • 4.4.3 Microarray
    • 4.4.4 Sanger Sequencing
    • 4.4.5 CRISPR
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurological Disorders
    • 4.5.4 Infectious Diseases
    • 4.5.5 Genetic Disorders
    • 4.5.6 Pharmacogenomics
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals and Clinics
    • 4.6.2 Research Institutes
    • 4.6.3 Pharmaceutical and Biotechnology Companies
    • 4.6.4 Diagnostic Laboratories
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Hardware
    • 4.7.2 Software
    • 4.7.3 Services
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Cloud-Based
    • 4.8.2 On-Premise
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Data Analysis
    • 4.9.2 Data Management
    • 4.9.3 Data Visualization

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Illumina
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Qiagen
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bio-Rad Laboratories
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Agilent Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Roche Diagnostics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Perkin Elmer
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Pacific Biosciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Oxford Nanopore Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 BGI Genomics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Genewiz
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Genscript Biotech
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 LGC Biosearch Technologies
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Takara Bio
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Fluidigm Corporation
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 10x Genomics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Personalis
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Myriad Genetics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Genomic Health
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Natera
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us